Phase 2 N=18 Dysport for the Treatment of OMD
Oral Dystonia · Tardive Dystonia
Primary: Mean Global Dystonia Rating Scale Score as Measured by Blinded Rater — 3.80; 3.57; 3.71 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=7 Efficacy of Levetiracetam in Oromandibular and Cranial Dystonia
Oromandibular Dystonia · Cranial Dystonia
Primary: Percent Change of the Sum of the Eyes, Mouth, Speech and Swallowing Subscores of the Burke-Fahn-Marsden (BFM) Dystonia Scale. — 12.16; 31.25 percent change
N/A N=9 rTMS and Botulinum Toxin in Primary Cervical Dystonia
Primary Cervical Dystonia · Dystonia
Primary: Dystonia Severity as Assessed by the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) — 13; 17 scores on a scale
N/A N=8 Identification of Optimal Stimulation Site for Cervical Dystonia Symptoms: An Exploratory Study
Cervical Dystonia · Spasmodic Torticollis
Primary: Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) — -3.0; 0.25; -2.9; -1.5 units on a scale
N/A N=6 Thalamic Deep Brain Stimulation for Spasmodic Dysphonia- DEBUSSY Trial
Spasmodic Dysphonia · Laryngeal Dystonia · Deep Brain Stimulation
Primary: Unified Spasmodic Dysphonia Rating Scale (USDRS) — 2.5; 3.75 units on a scale — p=0.025
Phase 2 N=16 Amlodipine Plus Botulinum Toxin for Focal Dystonia
Focal Dystonia
Primary: Toronto Western Spasmodic Torticollis Rating Scale (TWSTR) Sum Score — -6.00; -3.23 units on a scale
N/A N=53 Dynasplint Therapy for Trismus in Head and Neck Cancer
Trismus
Primary: Number of Participants Demonstrating Improved MIO Using Either the Dynapslint System or Tongue Depressors — 12; 12; 7; 7 participants
N/A N=20 rTMS in Spasmodic Dysphonia
Spasmodic Dysphonia · Laryngeal Dystonia
Primary: Adverse Response to rTMS — 0; 0 Participants
N/A N=24 Duloxetine for Treatment of Painful Temporomandibular Joint Disorder
Temporomandibular Joint Disorders
Primary: Spontaneous Pain as Measured by Visual Analog Scale at Baseline and at End of 6 Weeks. — 42.9; 51.4; 30.4; 44 units on a scale
N/A N=14 Study of a New Technique to Improve the Symptoms of Orofacial Discomfort in Patients With Peripheral Facial Paralysis
Peripheral Nerve Facial Nerve Paralysis · Facial Nerve Diseases · Orofacial Pain
Primary: The Visual Analog Scale for Pain Was Used to Grade Discomfort in Chewing After the Installation of Facial Paralysis. Level Zero is the Lack of Discomfort and 10 is the…
N/A N=24 Motor Cortex as a Research & Therapeutic Target in TMD
Temporomandibular Joint Disorders
Primary: Number of Participants With Pain Relief as Measured by Visual Analog Scale (VAS) Decrease of 50% or Greater From Baseline — 4; 9 participants
N/A N=5 Dystonia Treatment With Injections Supplemented By Transcranial Magnetic Stimulation
Cervical Dystonia
Primary: Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) — 17; 16.6; 17; 15.8 score on a scale — p=0.691
N/A N=5 Thalamic Deep Brain Stimulation for Secondary Dystonia in Children and Young Adults
Dystonia
Primary: Change From Baseline in Burke-Fahn-Marsden Dystonia Rating Scale — 14.7 change in points on a scale
N/A N=38 Unlocking Dystonia From Parkinson's Disease With Directional DBS Technology
Dystonia-Parkinsonism, Adult-Onset · Parkinson Disease
Primary: Burke-Fahn-Marsden Dystonia Rating Scale — 3.5 units on a scale — p=<0.001
Phase 2 N=21 Occlusal Adjustment as Treatment for Chronic Orofacial Pain
Temporomandibular Joint Disorders · Orofacial Pain
Primary: Visual Analogic Scale for Pain Intensity (0-10) — 6.52; 4.8; .81; 2.05 units on a scale
N/A N=81 Myofunctional Training for Obstructive Sleep Apnea Patients After Transoral Robotic Surgery
Sleep Apnea, Obstructive
Primary: Apnea Hypopnea Index (AHI) — 44.89; 44.65; 36.87 events per hour — p=<0.05
N/A N=80 Conservative Treatment of Patients With Temporomandibular Disorders
Temporomandibular Disorders
Primary: Patient-Rated TMD Pain, an 11 Point Numerical Rating Scale (NRS) — 0.9; 1.4; 1.6; 0.7 units on a scale
Phase 2 N=21 Incobotulinum Toxin A (Xeomin®) As A Treatment For Focal Task-Specific Dystonia Of The Musician's Hand
Dystonia
Primary: Physician Global Perception of Change - Blinded Rater 1 — 1; 1; 1; 4 Participants
Phase 2 N=22 DaxibotulinumtoxinA Injection for Treatment of Adductor Spasmodic Dysphonia
Adductor Spasmodic Dysphonia · Voice Disorders · Spasmodic Dysphonia
Primary: Our Primary Outcome is the Difference in VHI-10 Score at 30 Days After Injection With DAXI. — 17.81 units on a scale — p=<0.001
Phase 3 N=108 Sodium Oxybate in Spasmodic Dysphonia and Voice Tremor
Spasmodic Dysphonia · Voice Tremor
Primary: Symptom Severity — 28.0; 18.6; 14.2; 12.3 score on a scale — p=0.01
Phase 4 N=10 Botox for Cervical Dystonia Following EMG Mapping
Cervical Dystonia
Primary: Pre- and Post-injection Toronto Western Spasmodic Torticollis Rating Scale(TWSTRS): Global Clinical Impression Scale (GCI); Visual Analog Scale(VAS)
N/A N=171 Assessing a New Jaw Support Device During Third Molar Extractions
Impacted Third Molar Tooth · Temporomandibular Disorder
Primary: Occurrence of Pain at Follow-up With Wide Opening, or Pain in the Temple, Jaw Joint or Jaw Muscles. — 26; 32; 54; 53 Participants
Phase 2 N=10 Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism
Sialorrhea
Primary: Objectively Measured Salivary Weight — -0.07; -0.68 gm
Phase 4 N=16 Quantifying Musical Performance After Treatment With Myobloc in Musician's Dystonia
Focal Dystonia
Primary: Note Errors (Related to Errors in Duration) — 8.20; 5.79 msec — p==0.06
N/A N=20 Dental Appliance for Parkinson's Disease
Parkinson Disease
Primary: Changes in Gait Velocity — 1.10; 1.15 m/s
N/A N=1,046 CD-PROBE: Cervical Dystonia Patient Registry for the Observation of onabotulinumtoxinA Efficacy
Cervical Dystonia
Primary: Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) Total Score — 27.1 score on a scale
N/A N=9 Deep Brain Stimulation in Patients With Dystonia
Dystonia
Primary: The Toronto Western Spasmodic Rating Scale (TWSTRS) Movement Scores Measured Before DBS Surgery (Baseline) and at 12 Months — 33.5 TWSTRS total score change
Phase 2 N=53 Voice Tremor in Spasmodic Dysphonia: Central Mechanisms and Treatment Response
Spasmodic Dysphonia · Voice Tremor
Primary: Number of Participants Who Reported Positive Effects. — 17; 20 Participants
N/A N=12 Neuromodulation Therapy for Task-Specific Dystonia
Isolated Focal Hand Dystonia
Primary: Feasibility of Accurately Delivering TMS During the Task of Writing as Measured by Number of Participants Who Completed the TMS Sessions — 12; 12; 11 Participants
N/A N=12 rTMS and Botulinum Toxin in Benign Essential Blepharospasm
Benign Essential Blepharospasm
Primary: Change in JRS Severity Score — -1.8; -0.1 Change in score